Rigel reported Q4 2025 total revenues of USD 69.8 million, including net product sales of USD 65.4 million (up 41%) and contract revenues of USD 4.4 million. Q4 net income was USD 268.1 million, reflecting a USD 245.9 million non-cash deferred income tax benefit. For FY 2025, Rigel posted total revenues of USD 294.3 million, including net product sales of USD 232.0 million (up 60%) and contract revenues of USD 62.3 million. FY net income was USD 367.0 million, also including a USD 245.9 million non-cash deferred income tax benefit. Cash, cash equivalents and short-term investments were USD 155.0 million at Dec. 31, 2025. In commercial updates, Q4 2025 net product sales included Tavalisse USD 45.6 million (up 47%), Gavreto USD 10.2 million (up 27%), and Rezlidhia USD 9.6 million (up 29%). In pipeline highlights, enrollment is ongoing in the dose expansion phase of the Phase 1b R289 study in relapsed or refractory lower-risk MDS, with Rigel expecting to complete enrollment and select the recommended Phase 2 dose in H2 2026 and share preliminary dose expansion data by end-2026; updated dose escalation data presented at ASH showed 33% (6/18) RBC transfusion independence (at least 8 weeks) among evaluable transfusion-dependent patients at doses of 500 mg QD and higher. Corporate updates included the appointment of Michael P. Miller to Rigel’s board effective Feb. 1, 2026. For 2026, Rigel guided for total revenues of USD 275 million to USD 290 million, including net product sales of USD 255 million to USD 265 million and contract revenues of USD 20 million to USD 25 million, and said it expects positive net income for the year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603031601PR_NEWS_USPR_____SF00067) on March 03, 2026, and is solely responsible for the information contained therein.
Comments